FOGHORN THERAPEUTICS INC

Foghorn Therapeutics is a preclinical-stage biotechnology company whose research and development pipeline is built on animal testing. The company’s core platform and drug discovery programs rely on in vivo studies using animal models to advance its therapeutic candidates. As a company with no approved products, its primary operational activity is preclinical research, which inherently involves the commercial exploitation of animals for biomedical testing.

This exclusion is based on the company’s business model as a biotech firm engaged in animal-based research. No specific, recent enforcement actions or penalties against Foghorn Therapeutics itself were identified in the provided evidence. The general evidence references large penalties for animal welfare violations at research facilities and monitoring by watchdog groups, which reflects the systemic regulatory and ethical landscape within which such preclinical biotech companies operate. Without a revenue-generating product, the company’s reliance on animal testing constitutes its central commercial activity.